Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity

Yuan Rong, Vladimir E. Belozerov, Carol Tucker-Burden, Gang Chen, Donald L. Durden, Jeffrey J. Olson, Erwin G. Van Meir, Nigel Mackinan, Daniel J. Brat

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Hypoxia and necrosis are fundamental features of glioblastoma (GBM) and their emergence is critical for the rapid biological progression of this fatal tumor; yet, underlying mechanisms are poorly understood. We have suggested that vaso-occlusion following intravascular thrombosis could initiate or propagate hypoxia and necrosis in GBM. Tissue factor (TF), the main cellular initiator of coagulation, is overexpressed in GBMs and likely favors a thrombotic microenvironment. Epidermal growth factor receptor (EGFR) amplification and PTEN loss are two common genetic alterations seen in GBM but not in lower-grade astrocytomas that could be responsible for ÏF up-regulation. The most frequent EGFR mutation in GBM involves deletion of exons 2 to 7, resulting in the expression of a constitutively active receptor, EGFRvIII. Here, we show that overexpression of EGFR or EGFRvIH in human glioma cells causes increased basal TF expression and that stimulation of EGFR by its ligand, EGF, leads to a marked dose-dependent up-regulation of TF. In all cases, increased TF expression led to accelerated plasma coagulation in vitro. EGFR-mediated TF expression depended most strongly on activator protein-1 (AP-1) transcriptional activity and was associated with c-Jun NH 2-terminal kinase (JNK) and JunD activation. Restoration of PTEN expression in PTEN-deficient GBM cells diminished EGFR-induced TF expression by inhibiting JunD/AP-1 transcriptional activity. PTEN mediated this effect by antagonizing phosphatidylinositol 3-kinase activity, which in turn attenuated both Akt and JNK activities. These mechanisms are likely at work in vivo, as EGFR expression was highly correlated with TF expression in human high-grade astrocytoma specimens.

Original languageEnglish (US)
Pages (from-to)2540-2549
Number of pages10
JournalCancer Research
Volume69
Issue number6
DOIs
StatePublished - Mar 15 2009

Fingerprint

Transcription Factor AP-1
Thromboplastin
Glioblastoma
Epidermal Growth Factor Receptor
Astrocytoma
Necrosis
Phosphotransferases
Up-Regulation
Phosphatidylinositol 3-Kinase
Epidermal Growth Factor
Glioma
Exons
Thrombosis
Ligands
Mutation
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. / Rong, Yuan; Belozerov, Vladimir E.; Tucker-Burden, Carol; Chen, Gang; Durden, Donald L.; Olson, Jeffrey J.; Van Meir, Erwin G.; Mackinan, Nigel; Brat, Daniel J.

In: Cancer Research, Vol. 69, No. 6, 15.03.2009, p. 2540-2549.

Research output: Contribution to journalArticle

Rong, Y, Belozerov, VE, Tucker-Burden, C, Chen, G, Durden, DL, Olson, JJ, Van Meir, EG, Mackinan, N & Brat, DJ 2009, 'Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity', Cancer Research, vol. 69, no. 6, pp. 2540-2549. https://doi.org/10.1158/0008-5472.CAN-08-1547
Rong, Yuan ; Belozerov, Vladimir E. ; Tucker-Burden, Carol ; Chen, Gang ; Durden, Donald L. ; Olson, Jeffrey J. ; Van Meir, Erwin G. ; Mackinan, Nigel ; Brat, Daniel J. / Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. In: Cancer Research. 2009 ; Vol. 69, No. 6. pp. 2540-2549.
@article{8f094f85500242e8ab2ffc92a899c987,
title = "Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity",
abstract = "Hypoxia and necrosis are fundamental features of glioblastoma (GBM) and their emergence is critical for the rapid biological progression of this fatal tumor; yet, underlying mechanisms are poorly understood. We have suggested that vaso-occlusion following intravascular thrombosis could initiate or propagate hypoxia and necrosis in GBM. Tissue factor (TF), the main cellular initiator of coagulation, is overexpressed in GBMs and likely favors a thrombotic microenvironment. Epidermal growth factor receptor (EGFR) amplification and PTEN loss are two common genetic alterations seen in GBM but not in lower-grade astrocytomas that could be responsible for {\"I}F up-regulation. The most frequent EGFR mutation in GBM involves deletion of exons 2 to 7, resulting in the expression of a constitutively active receptor, EGFRvIII. Here, we show that overexpression of EGFR or EGFRvIH in human glioma cells causes increased basal TF expression and that stimulation of EGFR by its ligand, EGF, leads to a marked dose-dependent up-regulation of TF. In all cases, increased TF expression led to accelerated plasma coagulation in vitro. EGFR-mediated TF expression depended most strongly on activator protein-1 (AP-1) transcriptional activity and was associated with c-Jun NH 2-terminal kinase (JNK) and JunD activation. Restoration of PTEN expression in PTEN-deficient GBM cells diminished EGFR-induced TF expression by inhibiting JunD/AP-1 transcriptional activity. PTEN mediated this effect by antagonizing phosphatidylinositol 3-kinase activity, which in turn attenuated both Akt and JNK activities. These mechanisms are likely at work in vivo, as EGFR expression was highly correlated with TF expression in human high-grade astrocytoma specimens.",
author = "Yuan Rong and Belozerov, {Vladimir E.} and Carol Tucker-Burden and Gang Chen and Durden, {Donald L.} and Olson, {Jeffrey J.} and {Van Meir}, {Erwin G.} and Nigel Mackinan and Brat, {Daniel J.}",
year = "2009",
month = "3",
day = "15",
doi = "10.1158/0008-5472.CAN-08-1547",
language = "English (US)",
volume = "69",
pages = "2540--2549",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity

AU - Rong, Yuan

AU - Belozerov, Vladimir E.

AU - Tucker-Burden, Carol

AU - Chen, Gang

AU - Durden, Donald L.

AU - Olson, Jeffrey J.

AU - Van Meir, Erwin G.

AU - Mackinan, Nigel

AU - Brat, Daniel J.

PY - 2009/3/15

Y1 - 2009/3/15

N2 - Hypoxia and necrosis are fundamental features of glioblastoma (GBM) and their emergence is critical for the rapid biological progression of this fatal tumor; yet, underlying mechanisms are poorly understood. We have suggested that vaso-occlusion following intravascular thrombosis could initiate or propagate hypoxia and necrosis in GBM. Tissue factor (TF), the main cellular initiator of coagulation, is overexpressed in GBMs and likely favors a thrombotic microenvironment. Epidermal growth factor receptor (EGFR) amplification and PTEN loss are two common genetic alterations seen in GBM but not in lower-grade astrocytomas that could be responsible for ÏF up-regulation. The most frequent EGFR mutation in GBM involves deletion of exons 2 to 7, resulting in the expression of a constitutively active receptor, EGFRvIII. Here, we show that overexpression of EGFR or EGFRvIH in human glioma cells causes increased basal TF expression and that stimulation of EGFR by its ligand, EGF, leads to a marked dose-dependent up-regulation of TF. In all cases, increased TF expression led to accelerated plasma coagulation in vitro. EGFR-mediated TF expression depended most strongly on activator protein-1 (AP-1) transcriptional activity and was associated with c-Jun NH 2-terminal kinase (JNK) and JunD activation. Restoration of PTEN expression in PTEN-deficient GBM cells diminished EGFR-induced TF expression by inhibiting JunD/AP-1 transcriptional activity. PTEN mediated this effect by antagonizing phosphatidylinositol 3-kinase activity, which in turn attenuated both Akt and JNK activities. These mechanisms are likely at work in vivo, as EGFR expression was highly correlated with TF expression in human high-grade astrocytoma specimens.

AB - Hypoxia and necrosis are fundamental features of glioblastoma (GBM) and their emergence is critical for the rapid biological progression of this fatal tumor; yet, underlying mechanisms are poorly understood. We have suggested that vaso-occlusion following intravascular thrombosis could initiate or propagate hypoxia and necrosis in GBM. Tissue factor (TF), the main cellular initiator of coagulation, is overexpressed in GBMs and likely favors a thrombotic microenvironment. Epidermal growth factor receptor (EGFR) amplification and PTEN loss are two common genetic alterations seen in GBM but not in lower-grade astrocytomas that could be responsible for ÏF up-regulation. The most frequent EGFR mutation in GBM involves deletion of exons 2 to 7, resulting in the expression of a constitutively active receptor, EGFRvIII. Here, we show that overexpression of EGFR or EGFRvIH in human glioma cells causes increased basal TF expression and that stimulation of EGFR by its ligand, EGF, leads to a marked dose-dependent up-regulation of TF. In all cases, increased TF expression led to accelerated plasma coagulation in vitro. EGFR-mediated TF expression depended most strongly on activator protein-1 (AP-1) transcriptional activity and was associated with c-Jun NH 2-terminal kinase (JNK) and JunD activation. Restoration of PTEN expression in PTEN-deficient GBM cells diminished EGFR-induced TF expression by inhibiting JunD/AP-1 transcriptional activity. PTEN mediated this effect by antagonizing phosphatidylinositol 3-kinase activity, which in turn attenuated both Akt and JNK activities. These mechanisms are likely at work in vivo, as EGFR expression was highly correlated with TF expression in human high-grade astrocytoma specimens.

UR - http://www.scopus.com/inward/record.url?scp=65549089078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549089078&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-1547

DO - 10.1158/0008-5472.CAN-08-1547

M3 - Article

C2 - 19276385

AN - SCOPUS:65549089078

VL - 69

SP - 2540

EP - 2549

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 6

ER -